Synektik, a Polish listed supplier of medical technology and producer of radiopharmaceuticals, recorded improved results in the first half of fiscal year 2025/2026. Net profit from continuing operations rose by more than half to PLN 82.9 million, while total net profit reached PLN 331 million, including a one-time gain from the spin-off of the Syn2bio business.
Revenue from sales increased by 35% year-on-year to PLN 441.2 million, driven by strong growth in both the medical equipment and radiopharmaceutical segments. Operating profit climbed to PLN 107.7 million from PLN 71 million a year earlier, and EBITDA from continuing operations stood at PLN 118 million (up from PLN 80.9 million).
Medical equipment segment leads the way
The group’s core business – sales of advanced medical devices, IT solutions, and related services – surged 36% year-on-year to PLN 413.6 million (excluding intra‑group transactions). Synektik is the exclusive distributor of da Vinci surgical robots in Poland, the Czech Republic, and Slovakia, and is preparing to expand into the Baltic states and Ukraine.
Recurring revenues from consumables, services, and radiopharmaceuticals under long‑term contracts rose 28% to PLN 208 million. The radiopharmaceutical segment alone recorded a 17% increase in revenue, reaching PLN 27.5 million.
– We assume that the second half of the year will also be marked by dynamic business development, influenced by the ongoing intensive modernisation of the healthcare system in Poland using KPO funds – said CEO Cezary Kozanecki.
Order book expands and new markets open
In the first half of fiscal 2025/2026, Synektik secured contracts worth PLN 311 million – more than double the amount from the same period last year. The company is continuing its geographical expansion south of Poland, working on first deliveries to the Baltic states, and preparing to fully launch operations in Ukraine as a distributor of da Vinci systems.
The group maintains a strong balance sheet and expects further growth in the coming quarters, supported by increasing demand for robot‑assisted surgery and modernisation projects co‑financed by European funds.
Źródło: WNP.PL, Fot. Terelyuk/Shutterstock
